Online Program Home
My Program

Abstract Details

Activity Number:
88 - Biopharmaceutical Section A.M. Roundtable Discussion (Added Fee)
Type: Roundtables
Date/Time: Monday, July 30, 2018 : 7:00 AM to 8:15 AM
Sponsor: Biopharmaceutical Section
Abstract #330916
Title: Composite Endpoints for Alzheimer's Disease Clinical Trials
Author(s): Steve Edland*
Companies: University of California, San Diego
Keywords: clinical trials; statistical power; quantitative trait endpoints; MRI; Alzheimer's disease

Composite endpoints have received increasing attention as potential outcome measures for clinical trials in Alzheimer's disease. We have recently derived the weighted sum of component scales that maximize signal-to-noise of resulting composite scales (Ard et al. Optimal composite scores for longitudinal clinical trials under the linear mixed effects model. Pharm Stat. 2015;14(5):418­ 26) and maximizes their power as endpoints for clinical trials. This Discussion session with review concepts of composite scales using recent published examples of applications to volumetric MRI endpoints [Edland, et al. (2017) Alzheimer's & Dementia: Translational Research & Clinical Intervention. 2(3):177-181] and cognitive function endpoints [Edland et al. (2016) Alzheimer's & Dementia, doi: 10.1016/j.trci.2016.12.004] for clinical trials in Alzheimer's disease.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program